Precipio, Inc. announced on October 8, 2024, the launch of an expanded version of its Bloodhound MPN (Myeloproliferative Neoplasm) panel. This new panel is capable of distinguishing between CALR type 1 and type 2 mutations, which is crucial for disease prognosis and therapeutic decision-making.
The enhancement aligns with the latest National Comprehensive Cancer Network (NCCN) guidelines, Version 2.2024, released on August 8, 2024. Precipio states this is the only quantitative PCR-based panel of its kind on the market that offers this specific differentiation alongside other relevant genes for MPN evaluation.
This technological advancement provides healthcare providers with more detailed information regarding CALR mutations, enabling better management of MPN patient care. The ability to specify an MPN subtype and determine which CALR-positive patients may respond to CALR-targeted therapies enhances the clinical value of Precipio's offerings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.